TGR-1202: Phase I/II started

TG Therapeutics said investigators began an open-label, U.S. Phase I/II trial to evaluate 800 mg oral TGR-1202 once daily plus IV Kyprolis carfilzomib twice weekly for the first 3 weeks of each 4-week...